17,665 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by Intech Investment Management LLC

Intech Investment Management LLC purchased a new stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,665 shares of the company’s stock, valued at approximately $109,000.

Several other hedge funds have also added to or reduced their stakes in DSGN. Paloma Partners Management Co bought a new position in Design Therapeutics in the third quarter valued at approximately $64,000. China Universal Asset Management Co. Ltd. bought a new stake in Design Therapeutics in the fourth quarter valued at approximately $74,000. The Manufacturers Life Insurance Company bought a new stake in shares of Design Therapeutics in the 3rd quarter valued at $71,000. MetLife Investment Management LLC acquired a new stake in shares of Design Therapeutics during the third quarter worth about $104,000. Finally, PDT Partners LLC raised its holdings in Design Therapeutics by 33.1% during the 3rd quarter. PDT Partners LLC now owns 36,099 shares of the company’s stock worth $194,000 after buying an additional 8,972 shares during the period. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Trading Up 1.0 %

DSGN opened at $4.19 on Friday. The stock has a market capitalization of $237.84 million, a P/E ratio of -4.93 and a beta of 1.77. The firm’s fifty day simple moving average is $4.71 and its 200 day simple moving average is $5.34. Design Therapeutics, Inc. has a 12 month low of $3.15 and a 12 month high of $7.77.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. On average, equities research analysts predict that Design Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.